VivoSeq
Respiratory

Chronic Rhinosinusitis Without Nasal Polyps

10

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Chronic Rhinosinusitis Without Nasal Polyps is an early-stage landscape with 10 programs across 5 companies. The most active players are Sanofi, Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., Novartis. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

11/100

Mech. Concentration

75/100

Completion Rate

60/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2S

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2GSK logo

GSK

1 program

Phase 3Teva logo

Teva

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

8 of 10 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody220%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Recruiting2 · 22%
Active, not recruiting1 · 11%
Terminated1 · 11%
Unknown status1 · 11%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Recruiting·OOptinose US Inc.·Phase 3·NCT06850805·84 enrolled
A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07174115·30 enrolled
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT06691113·60 enrolled
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Completed·JJohns Hopkins University·Phase 2·NCT04362501·33 enrolled
Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
Completed·LLoma Linda University·N/A·NCT02927834·24 enrolled
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Completed·IInsmed Incorporated·Phase 2·NCT06013241·288 enrolled
Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Terminated·NNorthwestern University·Phase 4·NCT01676415·9 enrolled
Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Withdrawn·LLoma Linda University·Phase 4·NCT02119273
Prednisone in Chronic Rhinosinusitis Without Nasal Polyps
Unknown status·UUniversity of Chile·Phase 3·NCT02367118·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)